

VALEANT PHARMACEUTICALS INTERNATIONAL

Form 8-K

November 30, 2005

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

**FORM 8-K
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): November 30, 2005**

Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

1-11397
(Commission File Number)

33-0628076
(I.R.S Employer
Identification No.)

3300 Hyland Avenue
Costa Mesa, California 92626
(Address of principal executive offices) (Zip Code)
(714) 545-0100

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

TABLE OF CONTENTS

Item 7.01 Regulation FD Disclosure

Item 9.01 Financial Statements and Exhibits

SIGNATURES

EXHIBIT 99.1

EXHIBIT 99.2

Table of Contents

Item 7.01 Regulation FD Disclosure

On November 30, 2005, Valeant Pharmaceuticals International (the Company) presented certain information at the Lazard Capital Markets Life Sciences Conference. The presentation is attached as Exhibit 99.1. Exhibit 99.1 is also available on the Company's website at <http://valeant.com> under Investor relations/financial presentations dated November 30, 2005.

The presentation includes certain numerical measures that exclude amounts that are included in the most directly comparable measure calculated and presented in accordance with accounting principles generally accepted in the United States (GAAP). The Company uses certain non-GAAP financial measures, including adjusted net income (loss) from continuing operations and adjusted earnings before interest, taxes, depreciation and amortization, which excludes in-process research and development charges, sales force reduction costs and restructuring costs. Management excludes these items in assessing financial performance, primarily due to their non-operational nature or because they are outside of the Company's normal operations. The Company has provided this information because it believes that it is useful in assessing material changes in its financial condition and results of operations. A reconciliation of the non-GAAP numerical measures to the most directly comparable measures calculated in accordance with GAAP is attached as Exhibit 99.2. Exhibit 99.2 is also available on the Company's website at the website address above.

Item 9.01 Financial Statements and Exhibits

(c) Exhibits

Exhibit Number	Description
99.1	Presentation by the Company at the Lazard Capital Markets Life Sciences Conference.
99.2	Reconciliation of non-GAAP financial measures to the most directly comparable measure calculated in accordance with GAAP.

The information in this Current Report on Form 8-K, including the exhibits, will not be treated as filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into a filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 30, 2005

VALEANT PHARMACEUTICALS
INTERNATIONAL

By: /s/ Bary G. Bailey
Bary G. Bailey
Executive Vice President and Chief Financial
Officer

-3-

Table of Contents

Exhibit Index

Exhibit Number	Description
99.1	Presentation by the Company at the Lazard Capital Markets Life Sciences Conference.
99.2	Reconciliation of non-GAAP financial measures to the most directly comparable measure calculated in accordance with GAAP.